Determination of Regulatory Review Period for Purposes of Patent Extension; IMDELLTRA

Summary

The US Food and Drug Administration (FDA) has determined the regulatory review period for IMDELLTRA, a human biological product, following a patent extension application submitted to the US Patent and Trademark Office (USPTO).